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Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with
18F-fluorodeoxyglucose-positron-emission-tomography (PET). Since interim-PET is an important prognostic tool in
Hodgkin lymphoma (HL), the aim of this study was to investigate the expression of proteins involved in the
regulation of glucose metabolism in the different HL subtypes and their impact on clinical outcome.
Methods: Lymph node biopsies from 54 HL cases and reactive lymphoid tissue were stained for glucose
transporter 1 (GLUT1), lactate dehydrogenase A (LDHA) and lactate exporter proteins MCT1 and MCT4. In a second
series, samples from additional 153 HL cases with available clinical data were stained for GLUT1 and LDHA.
Results: Membrane bound GLUT1 expression was frequently observed in the tumor cells of HL (49% of all cases)
but showed a broad variety between the different Hodgkin lymphoma subtypes: Nodular sclerosing HL subtype
displayed a membrane bound GLUT1 expression in the Hodgkin-and Reed-Sternberg cells in 56% of the cases.
However, membrane bound GLUT1 expression was more rarely observed in tumor cells of lymphocyte rich classical
HL subtype (30%) or nodular lymphocyte predominant HL subtype (15%). Interestingly, in both of these lymphocyte
rich HL subtypes as well as in progressively transformed germinal centers, reactive B cells displayed strong
expression of GLUT1. LDHA, acting downstream of glycolysis, was also expressed in 44% of all cases. We evaluated
the prognostic value of different GLUT1 and LDHA expression patterns; however, no significant differences in
progression free or overall survival were found between patients exhibiting different GLUT1 or LDHA expression
patterns. There was no correlation between GLUT1 expression in HRS cells and PET standard uptake values.
Conclusions: In a large number of cases, HRS cells in classical HL express high levels of GLUT1 and LDHA
indicating glycolytic activity in the tumor cells. Although interim-PET is an important prognostic tool, a predictive
value of GLUT1 or LDHA staining of the primary diagnostic biopsy could not be demonstrated. However, we
observed GLUT1 expression in progressively transformed germinal centers and hyperplastic follicles, explaining false
positive results in PET. Therefore, PET findings suggestive of HL relapse should always be confirmed by histology.
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Hodgkin lymphoma (HL) is a common lymphoma in the
Western world. Most individuals affected are adolescents.
The tumor cells in HL, the Hodgkin- and Reed-Sternberg
(HRS) cells, are derived from germinal center B cells [1],
which have lost their B cell phenotype [2]. HRS cells repre-
sent only a minority in their reactive microenvironment,
which is mainly composed of T cells, epithelioid histiocytes,
and eosinophils [3]. Several signaling pathways have been
found to be constitutively deregulated in HL including
NF-kappaB, JAK-STAT, PI3K-Akt, ERK, AP1, NOTCH1
and receptor tyrosine kinases [4-8].
A hallmark of malignant tumors is the “Warburg
effect”—high glucose consumption and increased glycolytic
activity [9,10], which occurs as cancer cells shift their me-
tabolism from oxidative phosphorylation to much less effi-
cient glycolysis independent of their oxygen supply [11].
This needs to be compensated by increased glucose-
consumption. High glucose uptake by malignant
tumors is the pathophysiologic basis for imaging with
18F-fluorodeoxyglucose (FDG) positron emission to-
mography (PET). Thus, different PET studies have shown
high FDG uptake in HL [12,13]. Interim-PET, accom-
plished after the first cycles of chemotherapy, has proven
to be an important prognostic tool in HL [14-16]. Energy
independent glucose uptake into malignant and non-
malignant cells is regulated via the expression of glucose
transporter (GLUT) proteins [17,18]. GLUT1 and GLUT3,
which are both members of the SLC2A group, have high
affinity for glucose [19]. HRS cells were shown to express
GLUT1, whereas GLUT3 and Hexokinase II were either
not expressed or were only weakly expressed [20,21].
Because a correlation between GLUT1 protein expression
in lymphoma cells and FDG uptake in PET scan was
recently demonstrated [20-23], we investigated the possi-
bility that GLUT1 expression in HRS cells might also
predict clinical behavior.
In the cytoplasm, glucose is cleaved by glycolytic enzymes
into two molecules of pyruvate and is then transformed
into lactate by lactate dehydrogenase (LDH), which is a
tetramer composed of two different polypeptide chains,
LDHA and LDHB. Whereas LDHA favors the conversion
of pyruvate into lactate, LDHB is more efficient in conver-
ting lactate into pyruvate [24]. Lactate efflux results via
membrane-bound monocarboxylate transporters (MCT)
such as MCT1-4. MCT1 and 4 have low affinity for lactate,
which makes them ideal export molecules when the meta-
bolite is generated at high levels in the cytoplasm [24].
In the current study, we investigated the expression of
GLUT1, LDHA, MCT1 and MCT4 in tumor cells and
reactive bystander cells in different HL subtypes and in
respect to treatment outcome in a large number of patients.
All four proteins would be expected to be highly expressed
in cells exhibiting a high level of glucose metabolism, butwith exception of GLUT1, to our knowledge, have not been
investigated in Hodgkin lymphoma.
Methods
Tissues investigated consisted of paraffin embedded
whole tissue sections of normal lymphoid tissue (tonsils)
and 54 HL samples obtained from the archive files of the
Senckenberg Institute, which were stained for CD20,
CD3, CD15, LMP1, GLUT1, LDHA, MCT1 and MCT4
(patient details in Table 1). Routine pre-chemotherapy
PET data were available for eight patients. Furthermore,
10 lymph nodes with progressively transformed germinal
centers (PTGC) were stained for GLUT1. An additional
series of 153 classical HL with available clinical and PET
data were obtained from the Hematopathology Section, S.
Orsola-Malpighi Hospital, University of Bologna, and
stained in triplicate on tissue microarray (TMA) format
for GLUT1 and LDHA (patient details in Table 1). All
patients underwent pre-chemotherapy PET and Interim
PET after the two initial cycles of ABVD. SUVmax values
at the biopsy site of pre-chemotherapy PET data were
available in 13 patients. All patients were treated with
Doxorubicin, Bleomycin, Vinblastine and Dacarbazine
(ABVD). Patients underwent 2 or 6 courses of ABVD
depending on the disease stage. No treatment change was
made based on interim PET scan results. For the
pre-chemotherapy PET, a quantitative assessment of FDG
uptake was made by calculating the maximum standard
uptake value (SUVmax) in a region of interest within the
nodal or extranodal site showing the highest intensity of
FDG uptake. Immunostainings were performed as pre-
viously described [25] and were simultaneously assessed
by two pathologists (S.H., M.L.H) on a multi-head micro-
scope. The antibodies and detailed methods are listed in
Additional file 1: Table S1. Immunohistochemical stain-
ings and PET scans were reviewed without knowledge of
other findings.
Informed consent was obtained in accordance with the
Declaration of Helsinki and approval was obtained from
the ethics committees of the University Hospitals of
Frankfurt and Bologna. Statistical analyses were performed
using the statistical computing environment R [26]. The
data displayed a Gaussian distribution and for pairwise
comparisons Fisher's Exact Test was used. Progression
free survival (PFS) and overall survival (OS) were esti-
mated according to Kaplan-Meier [27]. PFS was defined
as the time from diagnosis to disease progression or death
from any cause. OS was defined as the time from diagno-
sis to death of any cause.
Results and discussion
Staining patterns in reactive tissue
In reactive tonsils, follicular dendritic cells (FDCs) in the
germinal centers as well as interfollicular plasma cells
Table 1 Clinical and pathological characteristics of the Hodgkin lymphoma patients studied for GLUT1 and LDHA
expression
HL cases Membrane bound GLUT1 expression Cytoplasmic LDHA expression
N 207 102/207 (49%) 68/153 (44%)
Age, median in years 34
Gender, male (%) 48
Histology
-Nodular sclerosis 140 79/140 (56%) 44/97 (45%)
-Mixed cellularity 29 12/29 (41%) 8/22 (36%)
-Lymphocyte-rich 10 3/10 (30%) 3/10 (30%)
-Lymphocyte-depleted 6 6/6 (100%) 4/6 (67%)
-NOS (not classifiable) 9 0/9 (0%) 3/5 (60%)







Bulky disease (%) 32
Interim-PET positive (%) 18
Treatment
- ABVD (%) 80
- ABVD + radiation (%) 20
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whereas small B lymphocytes in the mantle zone showed
moderate GLUT1 expression in all cases (Figure 1a,b).
Additionally, few interfollicular blasts, as well as basal
layers of squamous epithelium showed membrane bound
GLUT1 expression. No GLUT1 expression was observed
in CD3-positive lymphocytes in T cell areas. B cells in the
enlarged mantle zone in PTGC showed moderate GLUT1
expression, which may explain false positive results in
PET imaging [28,29]. LDHA was expressed in most ger-
minal center blasts, whereas interfollicular areas remained
negative. Membrane bound MCT1 expression was found
in very few germinal center blasts and basal squamous
epithelial layers. Interfollicular areas did not stain for
MCT1. Following a pattern similar to GLUT1, MCT4
was expressed by FDCs in the germinal centers, but was
not expressed in the mantle zones. Additionally, basal
squamous epithelial layers exhibited membrane bound
MCT4 expression.
GLUT1 expression in HL
Membrane bound GLUT1 expression was observed on
HRS cells in 102 of 207 HL cases (49%, Figure 1, Table 1).
Whereas membrane bound GLUT1 expression was
observed more frequently in lymphocyte depleted HL(LDCHL,100%), nodular sclerosing HL (NSCHL, 56%) and
mixed cellularity HL (MCCHL, 41%), membrane bound
GLUT1 expression was observed in only 15% of nodular
lymphocyte predominant HL (NLPHL) and in 30% of
lymphocyte rich classical HL (LRCHL). This is in line with
the study by Khandani et al. [20] in which no GLUT1
expression was found in the LP cells in two NLPHL investi-
gated, whereas GLUT1 expression was observed in three
NSCHL. Shim et al. [21] found expression of GLUT1 in 10
to 90% of HRS cells in four classical HL, including one
LDCHL, one NSCHL and two MCCHL; the highest rate
was observed in the NSCHL and the lowest rate in the
LDCHL. Glucose uptake and metabolism in the tumor
cells may, therefore, be less important in LP cells of
NLPHL than in HRS cells of classical HL, as suggested by
Hutchings et al., who, in a PET study, found significantly
lower standardized glucose uptake values in NLPHL than
in classical HL [13]. Nonetheless, a different study showed
that staging by PET scan is applicable in NLPHL [30]. We
observed GLUT1 expression in the reactive B cell infiltrate
in lymphocyte rich HL subtypes (Figure 1f), while the T
cell dominated areas were GLUT1-negative. If membrane
bound GLUT1 expression was observed in the HRS cells,
then GLUT1 was present in almost 100% of the tumor
cells regardless of the localization of the HRS cells in the
Figure 1 GLUT1 immunostaining. a, b. Reactive germinal centers showing membrane bound GLUT1 expression in follicular dendritic cells.
c. GLUT1 expression in the enlarged mantle zone of a progressively transformed germinal center. d. NSCHL with membrane bound GLUT1
expression by the HRS cells. e. NSCHL with granular cytoplasmic expression of GLUT1 by the HRS cells. f. NLPHL with GLUT1 expression in the
reactive B cells, but no GLUT1 expression in the LP cells.
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contribute to the PET positivity of HL in these cases via
their GLUT1 expression, although the tumor cells may be
a minority in the infiltrate. On the other hand, PET positiv-
ity of NLPHL is likely due to the strong glucose uptake in
the reactive B cells.
We then asked if different patterns of GLUT1 expres-
sion (negative, cytoplasmic or membrane bound) in the
primary biopsy had predictive value regarding progression
free survival and overall survival. However, we found no
significant prognostic value of the different GLUT1 stain-
ing patterns (Additional file 2: Figure S1), in contrast to
the powerful prognostic tool of interim-PET [16] and in
contrast to the prognostic impact of GLUT1 expression
found in other cancer types [31,32]. We also evaluated thepossibility that different patterns of GLUT1 expression
could predict the interim-PET result. However, no signifi-
cant association between the number of interim-PET posi-
tive cases and the pattern of GLUT1 staining was found
(Fisher's Exact Test, p = 0.6).
SUVmax values of pre-chemotherapy PET scans were
available for eight patients of the first series (stained on
full sections) and for 13 patients of the second series
(stained on TMA format). SUVmax values in the first
series were low to moderate (range 2.55 – 12.8), and a
tendency, albeit not significant, toward higher SUVmax
values in cases with membrane bound GLUT1 expression
was observed in the first series (Additional file 3: Figure
S2). In the second series the SUVmax values were ge-
nerally higher (range 4.1 – 18.9), but in this series, no
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values was observed. This may be simply a consequence of
the low number of cases with available pre-chemotherapy
PET data in either series. As well, immunohistochemical
staining on TMA may not be comparable to staining of full
sections. There may be different mechanisms of glucose
uptake, not only in the tumor cells, but also in the reactive
bystander cells. Potential alternative transporters like
GLUT3 and GLUT4 [33] were not investigated in the
present study. However, Khandani et al. [20] observed
GLUT3 expression in approximately 20% of the cells in the
microenvironment. It is possible, therefore, that different
mechanisms of glucose uptake, e.g., via GLUT1 in HRS
cells and via GLUT3 in the microenvironment, contribute
to PET positivity of the tumor.
Expression of LDHA and lactate transporter proteins in HL
Since membrane bound expression of GLUT1 suggests
increased glycolysis, the expression levels of LDHA, an
enzyme acting downstream of glycolysis, and of two lactate
transporters were investigated in the same HL cases.
Cytoplasmic LDHA expression was observed in a 68 out of
153 HL cases (44%, Table 1, Figure 2), with the highest
number of positive cases in the LDCHL subtype (67%).
However, no significant differences were observed with
respect to progression free survival and overall survival
(Additional file 2: Figure S1). This was somewhat surprisingFigure 2 LDHA, MCT4 and MCT1 immunostainings. a. NSCHL with stron
membrane bound expression of MCT4 in the LP cells. c. NSCHL with mem
nuclear staining for MCT1 in the HRS cells.because high serum LDH levels are known to be an adverse
prognostic factor for Hodgkin lymphoma patients [34].
As lactate must finally be exported from the cell, the
expression of two transporter proteins for lactate and
pyruvate, MCT1 and MCT4, were investigated in the first
series of cases. Compared to the number of cases expres-
sing GLUT1 and/or LDHA, only a few cases exhibited
membrane bound MCT1 or MCT4 expression (Figure 2).
MCT4 was expressed by tumor cells in 10 of 54 HL cases
(19%). Cases that did not show MCT4 expression by tumor
cells exhibited MCT4 expression in macrophages and
epithelioid cells. Membrane bound expression of MCT1
was observed in 13 of 54 HL cases (24%). Cytoplasmic as
well as nuclear MCT1 expression occurred in 13 (24%) and
4 cases (7%), respectively (Figure 2). There have been con-
flicting data regarding the expression of MCT1 and MCT4
in cancer. These were expressed in only few cases in the
present study. Similar to our observations, an inverse
correlation of GLUT1 and MCT1 expression was described
in colonic cancer [35]. Thus, lactate efflux appears to only
play a minor role in classical HL, possibly because the
dumping of excess carbon as lactate allows more rapid
incorporation of carbon into biomass.
Conclusions
We observed GLUT1 and/or LDHA expression in
the HRS cells of a large number of classical HL casesg cytoplasmic LDHA staining in the HRS cells. b. NLPHL with
brane bound expression of MCT1 in the HRS cells. d. LRCHL with
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Nevertheless, the expression pattern of these proteins
did not predict prognosis or survival, nor did it cor-
relate with interim-PET results. Powerful prognostic
tools like interim-PET cannot, therefore, be replaced by
applying these immunohistochemical stainings. How-
ever, we also observed GLUT1 expression in progres-
sively transformed germinal centers and hyperplastic
follicles, which can explain false positive results in PET.
Therefore, PET findings suggestive of HL relapse
should always be confirmed by histology.Additional files
Additional file 1: Table S1. Antibodies, dilutions, suppliers and
detection systems used in the present study.
Additional file 2: Figure S1. Kaplan-meier Analysis of GLUT1 and
LDHA expression as well as Interim PET. a. Kaplan-Meier Analysis of
different GLUT1 expression patterns (overall survival). b. Kaplan-Meier
Analysis of different GLUT1 expression patterns (progression free survival).
c. Kaplan-Meier Analysis of LDHA expression (overall survival). d. Kaplan-
Meier Analysis of LDHA expression (progression free survival). e. Kaplan-
Meier-Analysis of Interim-PET-positive and -negative cases (overall
survival). f. Kaplan-Meier-Analysis of Interim-PET-positive and -negative
cases (progression free survival).
Additional file 3: Figure S2. SUVmax in different GLUT1 expression
patterns. a. Prechemotheraphy SUVmax values in 8 patients of the first
series stained on full sections. b. Prechemotheraphy SUVmax values in 13
patients of the second series stained on TMA format.Competing interests
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